KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE

Depression and Anxiety

Volumn 33, Issue 8, 2016, Pages 698-710

  Bobo, William V ^a   Voort, Jennifer L Vande ^a   Croarkin, Paul E ^a   Leung, Jonathan G ^a   Tye, Susannah J ^a   Frye, Mark A ^a  

^a MAYO CLINIC   (United States)

Author keywords

bipolar depression; bipolar disorder; ketamine; major depression; treatment resistant depression

Indexed keywords

KETAMINE; MIDAZOLAM; PLACEBO;

ANXIETY; BIPOLAR DEPRESSION; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; CONFUSION; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCONVULSIVE THERAPY; ELEVATED BLOOD PRESSURE; HEADACHE; HEART RATE; HUMAN; LOW DRUG DOSE; MAJOR DEPRESSION; MENTAL DISEASE; MENTAL DISSOCIATION; MONOTHERAPY; OFF LABEL DRUG USE; PRIORITY JOURNAL; REMISSION; REVIEW; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT RESISTANT DEPRESSION; VERTIGO; VISUAL HALLUCINATION; XEROSTOMIA;

EID: 84979702232     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22505     Document Type: Review

References (94)

1. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006;7:137–151.
2. Altshuler LL, Frye MA, Gitlin MJ. Acceleration and augmentation strategies for treating bipolar depression. Biol Psychiatry 2003;53:691–700.
3. Abdallah CG, Averill LA, Krystal JH. Ketamine as a promising prototype for a new generation of rapid-acting antidepressants. Ann N Y Acad Sci 2015;1344:66–77.
4. Øye I. Ketamine analgesia, NMDA receptors and the gates perception. Acta Anaesthesiol Scand 1998;42:747–749.
5. Clements JA, Nimmo WA. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 1981;52:27–30.
6. Geisslinger G, Hering W, Thomann P, et al. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth 1993;70:666–671.
7. Reardon S. Rave drug tested against depression. Nature 2015;517:130–131.
8. Kellner CH, Greenberg RM, Ahle GM, Liebman LS. Electroconvulsive therapy is a standard treatment; ketamine is not (yet). Am J Psychiatry 2014;171:796.
9. Rasmussen KG. Has psychiatry tamed the “ketamine tiger?” Considerations on its use for depression and anxiety. Prog Neuropsychopharmacol Biol Psychiatry 2016;64:218–224.
10. Cusin C, Hilton GQ, Nierenberg AA, Fava M. Long-term maintenance with intramuscular ketamine for treatment-resistant bipolar II depression. Am J Psychiatry 2012;169:868–869.
11. Messer M, Haller IV. Maintenance ketamine treatment produces long-term recovery from depression. Primary Psychiatry 2010;17:48–50.
12. Messer M, Haller IV, Larson P, et al. The use of a series of ketamine infusions in two patients with treatment-resistant depression. J Neuropsychiatry Clin Neurosci 2010;22:442–444.
13. Segmiller F, Ruther T, Linhardt A, et al. Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 2013;53:996–998.
14. Szymkowicz SM, Finnegan N, Dale RM. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression. J Affect Disord 2013;147:416–420.
15. Schatzberg A. A word to the wise about ketamine. Am J Psychiatry 2014;171:262–263.
16. Lawrence J. The secret life of ketamine. Pharm J 2015;294:7854–7855. Available at: http://www.pharmaceutical-journal.com/news-and-analysis/features/the-secret-life-of-ketamine/20068151.article. Accessed on: December 29, 2015.
17. aan het Rot M, Zarate CA Jr., Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry 2012;72:537–547.
18. Rush AJ. Ketamine for treatment-resistant depression: ready or not for clinical use? Am J Psychiatry 2013;170:1079–1081.
19. Zarate CA Jr., Niciu MJ. Ketamine for depression: evidence, challenges and promise. World Psychiatry 2015;14:358–350.
20. Ketamine Advocacy Network. Available at: http://www.ketamineadvocacynetwork.org/. Accessed on: December 29, 2015.
21. Hamilton J. Club drug ketamine gains traction as a treatment for depression. National Public Radio. Available at: http://www.npr.org/sections/health-shots/2015/09/28/443203592/club-drug-ketamine-gains-traction-as-a-treatment-for-depression. Accessed on: December 29, 2015.
22. Pollack A. Special K, a hallucinogen, raises hopes and concerns as a treatment for depression. The New York Times 2014. Available at: http://www.nytimes.com/2014/12/10/business/special-k-a-hallucinogen-raises-hopes-and-concerns-as-a-treatment-for-depression.html?_r=0. Accessed on: December 29, 2015.
23. Diazgranados N, Ibrahim L, Brutsche NE, et al. Rapid resolution of suicidal ideation after a single infusion of an NMDA antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010;71:1605–1611.
24. Price RB, Nock M, Charney DS, Matthew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009;66:522–526.
25. Zarate C, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012;71:939–946.
26. Ballard ED, Ionescu DF, Vande Voort JL, et al. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res 2014;58:161–166.
27. Murrough JW, Soleimani L, deWilde KE, et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol Med 2015;45:3571–3580.
28. Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D 2015;15:37–43.
29. Warden D, Rush AJ, Trivedi MH, Fava M, Wisniewski SR. STAR*D project results: a comprehensive review of findings. Curr Psychiatry Rep 2007;9:449–459.
30. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59(6):530–537.
31. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003;60(3):261–269.
32. Frye MA, Prieto ML, Bobo WV, et al. Current landscape, unmet needs, and future directions for treatment of bipolar depression. J Affect Disord 2015;169(Suppl 1):S17–S23.
33. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163:217–224.
34. Post RM, Leverich GS, Altshuler LL, et al. An overview of recent findings of the Stanley Foundation Bipolar Network, pt 1. Bipolar Disord 2003;5:310–319.
35. Gitlin MJ, Swendsen J, Heller TL, Hammen C. Relapse and impairment in bipolar disorder. Am J Psychiatry 1995;152:1635–1640.
36. McElroy SL, Altshuler LL, Suppes T, et al. Axis I psychiatric comorbidity and its relationship to historical illness variables in 288 patients with bipolar disorder. Am J Psychiatry 2001;158:420–426.
37. Sylvia LG, Shelton RC, Kemp DE, et al. Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). Bipolar Disord 2015;17:212–223.
38. Tondo L, Isacsson G, Baldessarini R. Suicidal behavior in bipolar disorder: risk and prevention. CNS Drugs 2003;17:491–511.
39. Griffiths JJ, Zarate CA, Rasimas JJ. Existing and noval biological therapeutics in suicide prevention. Am J Prev Med 2015;47(3S2):S195–S203.
40. Diamond PR, Farmery AD, Atkinson S, et al. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic. J Psychopharmacol 2014;28:536–544.
41. Xu U, Hackett M, Carter G, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. Int J Neuropsychopharmacol November 17, 2015. pii: pyv124. doi:10.1093/ijnp/pyv124. [Epub ahead of print].
42. Newport DJ, Carpenter LL, McDonald WM, et al. Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 2015;172:950–966.
43. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2015;45:693–704.
44. Lee EE, Della Selva MP, Liu A, Himelhoch S. Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis. Gen Hosp Psychiatry 2015;37:178–184.
45. Romeo B, Choucha W, Fossati P, Rotge JY. Meta-analysis of short- and mid-term efficacy of ketamine in unipolar and bipolar depression. Psychiatry Res 2015;230:682–688.
46. Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol 2015;30:152–163.
47. Parsaik AK, Singh B, Khosh-Chashm D, Mascarenhas SS. Efficacy of ketamine in bipolar depression: systematic review and meta-analysis. J Psychiatr Pract 2015;21:427–435.
48. Fond G, Loundou A, Rabu C, et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 2014;231:3663–3676.
49. Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK. Ketamine as the prototype glutamatergic antidepressant: pharmacodynamics actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmacol 2014;4:75–99.
50. Murrough JW. Ketamine as a novel antidepressant: from synapse to behavior. Clin Pharm Ther 2012;91:303–309.
51. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351–354.
52. Zarate CA Jr, Singh JB, Carlson NE, et al. A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856–864.
53. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of an N-methyl-d-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010;67:793–802.
54. aan het Rot M, Collins KA, Murrough JW, et al. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 2010;67:139–145.
55. Murrough JW, Perez AM, Pillemer S, et al. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry 2012;74:250–256.
56. Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low-dose ketamine for major depression. J Psychopharmacol 2013;27:444–450.
57. Shiroma PR, Albott CS, Johns B, et al. Neurocognitive performance and serial intravenous subanesthetic ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 2014;17:1805–1813.
58. Lai R, Katalinic N, Glue P, et al. Pilot dose-response trial of i.v. ketamine in treatment-resistant depression. World J Biol Psychiatry 2014;15:579–584.
59. Cusin C, Ionescu DF, Pavone KJ, et al. Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation. Aust N Z J Psychiatry February 18, 2016. pii: 0004867416631828. [Epub ahead of print].
60. Wan L-B, Levitch CF, Perez AM, et al. Ketamine safety and tolerability in clinical trials for treatment-resistant depression. J Clin Psychiatry 2015;76:247–252.
61. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep 1962;10:799–812.
62. Ghasemi M, Kazemi MH, Yoosefi A, et al. Rapid antidepressant effects of repeated doses of ketamine compared with electroconvulsive therapy in hospitalized patients with major depressive disorder. Psychiatry Res 2014;215:355–361.
63. McGirr A, Berlim MT, Bond DJ, et al. A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability. J Psychiatr Res 2015;62:23–30.
64. Lodge D, Mercier MS. Ketmaine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol 2015;172:4254–4276.
65. Bobo WV, Miller SC. Ketamine as a preferred substance of abuse. Am J Addict 2002;11:332–334.
66. Schak KM, Vande Voort JL, Johnson EK, et al. Potential risks of poorly monitored ketamine use in depression treatment. Am J Psychiatry 2016;173:215–218.
67. Liu JX, Zerbo E, Ross S. Intensive ketamine use for multiple years: a case report. Am J Addict 2015;24:7–9.
68. Kalsi SS, Wood DM, Dargan PI. The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use. Emerg Health Threats J 2011;4:7107. doi:10.3402/ehtj.v4i0.7107.
69. Morgan CJ, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010;105:121–133.
70. Wood D. Ketamine and damage to the urinary tract. Addiction 2013;108:1515–1516.
71. Wang C, Zheng D, Xu J, Lam W, Yew DT. Brain damages in ketamine addicts as revealed by magnetic resonance imaging. Front Neuroanat 2013;7:23. doi:10.3389/fnana.201300023
72. Liao Y, Tang J, Fornito A, et al. Alterations in regional homogeneity of resting-state brain activity in ketamine addicts. Neurosci Lett 2012;522:36–40.
73. Murrough JW, Burdick KE, Levitch CF, et al. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial. Neuorpsychopharmacology 2015;40:1084–1090.
74. Neuchterlein KH, Green MF, Kern RS, et al. The MATRICS consensus cognitive battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008;165:203–213.
75. Murrough JW, Wan LB, Iacoviello B, et al. Neurocognitive effects of ketamine in treamtent-resistant major depression: association with antidepressant response. Psychopharmacol (Berl) September 11, 2013. [Epub ahead of print].
76. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Erlbaum; 1988.
77. Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin 2008;24:1329–1335.
78. Frye MA. Clinical practice. Bipolar disorder—a focus on depression. N Engl J Med 2011;364:51–59.
79. Lapidus KA, Levitch CF, Perez AM, et al. A randomized controlled trial of intranasal ketamine in major depressive disorder. Biol Psychiatry 2014;76:970–976.
80. Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013;170:1134–1142.
81. Sos P, Klirova M, Novak T, et al. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression. Neuroendocrinol Lett 2013;34:287–293.
82. Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychopharmacol 2015;35:334–336.
83. Qin P, Nordentoft M. Suicide risk in relation to psychiatric hospitalization: evidence based on longitudinal registers. Arch Gen Psychiatry 2005;62:427–432.
84. Borges S, Chen YF, Laughren TP, et al. Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration. J Clin Psychiatry 2014;75:205–214.
85. Miura T, Noma H, Furukawa TA, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2014;1:351–359.
86. Rabheru K. Maintenance electroconvulsive therapy (M-ECT) after acute response: examining the evidence for who, what, when, and how? J ECT 2012;28:39–47.
87. Ibrahim L, Diazgranados N, Franco-Chaves J, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012;37:1526–1533.
88. Kantrowitz JT, Halberstam B, Grangwisch J. Single-dose ketamine followed by daily d-cycloserine in treatment-resistant bipolar depression. J Clin Psychiatry 2015;76:737–738.
89. Radvansky BM, Puri S, Sifonios AN, Eloy JD, Le V. Ketmaine—a narrative review of its uses in medicine. Am J Ther April 24, 2015. [Epub ahead of print].
90. Gartlehner G, Thieda P, Hansen RA, et al. Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis. Drug Saf 2008;31:851–865.
91. Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction 2006;101:1212–1213.
92. Lankenau SE, Sanders B, Bloom JJ, et al. Prevalence and patterns of prescription drug misuse among young ketamine injectors. J Drug Issues 2007;37:717–736.
93. Iltis AS, Misra S, Dunn LB, et al. Addressing risks to advance mental health research. JAMA Psychiatry 2013;70:1363–1371.
94. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006;29:385–396.